Whole-Genome mRNA Gene Expression Differs Between Patients With and Without Delirium

Katrina Kalantar, BS1,*, Sara C. LaHue, MD2,3,*, Joseph L. DeRisi, PhD1, Hannah A. Sample, BS1, Caitlin A. Contag, BS4, Scott A. Josephson, MD2,3, Michael R. Wilson, MD2,3, and Vanja C. Douglas, MD2,3

Abstract

Objective: To identify differences in gene expression between patients with in-hospital delirium from a known etiology (urinary tract infection [UTI]) and patients with delirium from an unknown etiology, as well as from nondelirious patients. Methods: Thirty patients with delirium (8 with UTI) and 21 nondelirious patients (11 with UTI) were included in this prospective case–control study. Transcriptomic profiles from messenger RNA sequencing of peripheral blood were analyzed for gene expression and disease-specific pathway enrichment patterns, correcting for systemic inflammatory response syndrome. Genes and pathways with significant differential activity based on Fisher exact test \( (P < .05, |Z\) score \( >2) \) are reported. Results: Patients with delirium with UTI, compared to patients with delirium without UTI, exhibited significant activation of interferon signaling, upstream cytokines, and transcription regulators, as well as significant inhibition of actin cytoskeleton, integrin, paxillin, glioma invasiveness signaling, and upstream growth factors. All patients with delirium, compared to nondelirious patients, had significant complement system activation. Among patients with delirium without UTI, compared to nondelirious patients without UTI, there was significant activation of elf4 and p7056 k signaling. Conclusions: Differences exist in gene expression between delirious patients due to UTI presence, as well as due to the presence of delirium alone. Transcriptional profiling may help develop etiology-specific biomarkers for patients with delirium.

Keywords
delirium, urinary tract infection, transcriptome, RNA sequencing

Introduction

Delirium is an acute cognitive disorder characterized by fluctuations in attention and awareness. Approximately 18% to 35% of elderly patients present to the hospital with delirium, and 10% to 15% develop delirium during hospitalization, with increased incidences among critically ill patients.1-3 Delirium is associated with increased health-care utilization leading to greater hospitalization costs,4 longer hospital stays,4,5 and worse clinical outcomes.5-7

Identification of delirium’s cause is imperative for its treatment. There are numerous factors that increase delirium risk, including advanced age5,8, baseline cognitive,9 hearing, or vision impairments2,10,11; presence of infection12; and polypharmacy.13,14 Patients suspected of having delirium often undergo extensive testing of serum, urine, and cerebrospinal fluid; electroencephalography; and neuroimaging.5 However, such an indiscriminate workup is inefficient and costly, and despite this, the cause of delirium in many patients remains unknown.

One method for classifying diseases by type and pathogenesis is through identification of unique gene expression signatures.15-17 RNA sequencing (RNA-Seq)18 uses next-generation sequencing technologies to efficiently quantify gene transcripts in a biological sample across the whole human genome with high fidelity.19 While previous studies focused on a narrow set of inflammatory markers that are believed a priori to play a role in delirium pathophysiology, profiling the whole transcriptome allows for a more unbiased approach in identifying particular

1 Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA
2 Department of Neurology, School of Medicine, University of California, San Francisco, San Francisco, CA, USA
3 Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
4 School of Medicine, University of California, San Francisco, San Francisco, CA, USA
* The two authors Katrina Kalantar and Sara C. LaHue are co-first authors and have contributed equally to this project.
Received 3/22/2018. Received revised 6/7/2018. Accepted 6/7/2018.
Corresponding Author:
Vanja C. Douglas, 505 Parnassus Ave, M798, San Francisco, CA 94143, USA.
Email: vanja.douglas@ucsf.edu
genes and pathways that are differentially up- or downregulated in delirium.20-22 Our study is the first to implement RNA-Seq in delirium research. We hypothesized that patients with in-hospital delirium associated with a urinary tract infection (UTI) will have differences in mRNA gene expression in comparison with patients with delirium due to other causes, as well as compared to patients hospitalized without delirium, with or without an UTI.

Methods
Study Participants
This prospective case–control study took place from July 2014 through March 2015. Patients were identified on the neurology or medicine services at a tertiary referral hospital; patients with delirium or UTI were eligible for inclusion. All patients admitted to the neurology and medicine services were prospectively screened in the electronic medical record daily (H.A.S., V.C.D.) for altered mental status and/or presence of UTI. The primary physician caring for the patient was contacted to determine whether or not the patient met the inclusion criteria. If the patient met the inclusion criteria, H.A.S. approached him or her for consent, specimen collection, and a brief interview. Delirium was confirmed using the confusion assessment method by a board-certified neurologist (V.C.D.).23 Blood samples were collected from cases within 24 hours of delirium diagnosis in all but 2, where blood was obtained within 48 hours of diagnosis. Delirium was attributed to the UTI when the 2 conditions occurred contemporaneously and when there was no other more likely cause of the delirium. Urinary tract infection was defined as a urinalysis with the presence of white cells and a urine culture with greater than 100 000 colony-forming units of an infectious organism. Patients cared for by a surgical service were excluded. Information about cognitive impairment, mobility, hearing, and vision was obtained from the patient or an informant when possible. Informants were asked about baseline cognitive function using the IQCode.24 In cases where the informant was not available and the patient could not provide the information, these data were obtained from chart review. Statistical comparisons between the 2 groups were calculated using a 2-sample unequal variance t test.

Standard Protocol Approvals, Registrations, and Patient Consents
We obtained consent for study enrollment from each patient or the patient’s surrogate decision maker. Eligible patients were enrolled under a research protocol (#13-12557) approved by the institutional review board of the University of California, San Francisco.

Peripheral Blood Mononuclear Cell Isolation
Patient blood samples were collected in tubes with a preservative solution containing trisodium citrate, citric acid, and dextrose.

Figure 1. First, RNA was extracted from PBMCs and sequenced on Illumina HiSeq 2500. The .fastq files obtained from sequencing were quality filtered using PRICESeqFilter and subsequently aligned to HG38 using STAR aligner. After alignment, quality control filters included removal of samples with less than 60% uniquely mapped reads, removal of nonprotein-coding genes, removal of ribosomal and mitochondrial rRNA, and removal of genes with zero read counts in greater than 75% of samples. After quality control, differential expression analysis was performed using DESeq2 on each of the 6 cross sections of the data shown. Genes with raw P value < .05, for each comparison, were included in ingenuity pathways analysis. PBMC indicates peripheral blood mononuclear cell; rRNA, ribosomal ribonucleic acid STAR, spliced transcripts alignment to reference.

Tubes were centrifuged, and the plasma fraction was removed. The blood sample was diluted to a 1:1 ratio with phosphate-buffered saline (PBS). Diluted blood was layered onto 10 mL of Ficoll mixture and centrifuged. After removing the top layer, the cells in theuffy coat were transferred, washed with PBS, counted, spun down, and stored in liquid nitrogen.

RNA Sequencing Library Preparation
RNA was extracted from each peripheral blood mononuclear cell sample and was depleted of ribosomal RNA using Ribo-Zero, (Illumina, San Diego, California CA) (Figure 1). The Illumina TruSeq, (Illumina, San Diego, CA) protocol was utilized to generate RNA-Seq libraries from 1 to 2 ng of RNA/sample. Samples were individually barcoded, allowing for the libraries to be pooled and sequenced together on an Illumina HiSeq 4000 machine.

Transcript Alignment and Quality Filtering
Reads were quality filtered using PriceSeqFilter25 and then aligned to the human genome (NCBI GRCh-38) using the spliced transcripts alignment to reference (STAR) aligner.26 Summing all samples together, there were 542 251 466 total reads.
single-end 50 base-pair reads. Samples with less than 50% uniquely mapping reads were discarded from the analysis. Abundance of aligned reads mapping to transcripts was estimated by STAR. Transcript counts were filtered to include only genes listed with biotype “protein-coding” in the ENSEMBL database. Mitochondrial and ribosomal RNA genes were removed along with genes with zero-mapped reads in $\geq$75% of samples to reduce spurious differential expression results.

**Differential Expression Analysis**

Differential expression analysis was performed using DESeq2 on cross sections of the patient data to understand how each of the conditions impacted the disease phenotype. In a preliminary analysis, differential expression was performed without correcting for potential confounding variables. However, after observing upregulation of numerous inflammatory markers, we added a correction for systemic inflammatory response syndrome (SIRS) by including a binary variable for SIRS status in the DESeq2 model for differential expression. Systemic inflammatory response syndrome status was determined at the time of study enrollment based on standard SIRS criteria, determined by meeting 2 or more of the following: temperature greater than 38°C or less than 36°C, heart rate greater than 90 beats per minute, respiratory rate greater than 20 breaths per minute, and white blood count greater than 12 000 or less than 4000. We calculated $P$ values and adjusted $P$ values using Benjamini-Hochberg multiple test correction to determine the false discovery rate. However, given that fewer than 10 genes were significant at $P_{adj} < .05$ across all comparisons, all genes with unadjusted $P$ value $<.05$ were selected as inputs to the pathway functional enrichment analysis as described below.

**Pathway Functional Enrichment Analysis**

GO enrichment analysis was performed using the ToppGene enrichment analysis tool to identify biological processes overrepresented in the list of differentially expressed genes with an unadjusted $P < .05$. Qiagen’s Ingenuity Pathway Analysis (IPA) software (QIAGEN, Redwood City, California) was used to further understand the activation and repression of specific pathways. Genes with unadjusted $P < .05$ were input into the core analysis function using the Ingenuity database as the null model. Ingenuity Pathway Analysis–canonical pathway analysis aims to identify pathways that are significantly over- or underrepresented, while the IPA upstream regulator analysis seeks to identify the upstream transcriptional regulators that can explain the observed gene expression. Results from the canonical pathways and upstream regulator analysis were interpreted with respect to the existing literature on delirium. The software computed a Fisher exact test $P$ value, which was not corrected for multiple testing. Ingenuity Pathway Analysis provides 2 metrics for evaluation of the significance of results: the overlap $P$ value and $z$ score. The overlap $P$ value, calculated as a Fisher exact test, indicates the enrichment of genes in a pathway without taking into account the regulation direction. Meanwhile, the $z$ score assesses the correlation of observed and predicted up-/downregulation patterns. Analysis of these results focused only on pathways that were both significant at unadjusted $P < .05$ and $|z$ score$| > 2$.

**Hierarchical Clustering of Transcriptome Profile**

Genes differentially expressed in the comparison of all delirious versus nondelirious patients at unadjusted $P < .01$ were used as features for hierarchical clustering to demonstrate the separability between the 2 clinical classifications based on their transcriptome profiles. The rlog transformation from the DESeq2 package was applied to the normalized gene counts. The data were centered and scaled prior to clustering. Clustering was performed using the hclust function in the R v 3.3.1 statistical package with Euclidean distance and complete linkage and visualized via the heatmap.2 function from the R v 3.3.1 gplots package.

**Results**

**Study Participants**

There were 75 patients who met criteria and were approached for inclusion. Fifty one were included in the analysis, 30 with delirium and 21 without at the time of blood specimen collection. The remaining 24 patients were not included for the following reasons: refusal to participate (14), lack of a surrogate for consent (2), discharge from hospital prior to blood specimen collection (4), or low numbers of uniquely aligned reads or low numbers of unique transcripts, which are indicators of low-quality libraries during sequencing that may erroneously skew the analysis. Thirty hospitalized patients with delirium were included, including 8 patients with delirium attributed to UTI. Alternate causes of delirium included infection (non-UTI; 3 patients), medication toxicity (3), metabolic state (4), neoplastic state (3), postictal state (1), and a combination of categories (6). Twenty-one hospitalized controls without delirium were enrolled, 11 of whom were diagnosed with an UTI.

The mean age of patients with delirium was 69 (13) years, compared with 59 (17) years in patients without delirium ($P = .04$). Patients both with and without delirium were hospitalized for a broad range of primary diagnoses (Supplemental Table). Of the patients with delirium, 7 (23%) met SIRS criteria, compared with 1 (5%) patient without delirium ($P = .05$). Overall, patients with delirium were older and more likely to be diagnosed with dementia compared to the patients without delirium (Table 1).

**Analysis of Delirium of Different Etiologies**

The mean percentage of uniquely aligned reads across all the participants was 79.8%, and mean total gene counts were 3.0 million. Filtering for protein coding genes reduced the mean number of gene counts per sample to 2.2 million. Differential gene expression analysis of patients with delirium resulting from an UTI versus delirium resulting from unknown etiologies identified 440 differentially expressed genes at an unadjusted $P < .05$. Among these differentially expressed genes, ToppGene...
Table 1. Demographics and Clinical Characteristics of Study Participants.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Delirium+, Mean (SD)</th>
<th>Delirium−, Mean (SD)</th>
<th>Delirium+ Versus Delirium− P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years (SD)</td>
<td>UTI+ (n = 8)</td>
<td>UTI− (n = 22)</td>
<td>0.04</td>
</tr>
<tr>
<td></td>
<td>76 (5)</td>
<td>66 (14)</td>
<td></td>
</tr>
<tr>
<td>Women, n (%)</td>
<td>UTI+ (n = 11)</td>
<td>UTI− (n = 10)</td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td>6 (55%)</td>
<td>2 (20%)</td>
<td></td>
</tr>
<tr>
<td>Positive SIRS criteria, n (%)</td>
<td>UTI+ (n = 3)</td>
<td>UTI− (n = 1)</td>
<td>0.05</td>
</tr>
<tr>
<td></td>
<td>3 (38%)</td>
<td>1 (9%)</td>
<td></td>
</tr>
<tr>
<td>Dementia, n (%)</td>
<td>UTI+ (n = 1)</td>
<td>UTI− (n = 1)</td>
<td>.006</td>
</tr>
<tr>
<td></td>
<td>1 (13%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Mild cognitive impairment, n (%)</td>
<td>UTI+ (n = 3)</td>
<td>UTI− (n = 1)</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>3 (38%)</td>
<td>1 (9%)</td>
<td></td>
</tr>
<tr>
<td>Alcohol use disorder, n (%)</td>
<td>UTI+ (n = 0)</td>
<td>UTI− (n = 0)</td>
<td>0.7</td>
</tr>
<tr>
<td></td>
<td>0 (0%)</td>
<td>1 (10%)</td>
<td></td>
</tr>
<tr>
<td>Poor vision, n (%)</td>
<td>UTI+ (n = 0)</td>
<td>UTI− (n = 0)</td>
<td>0.8</td>
</tr>
<tr>
<td></td>
<td>0 (0%)</td>
<td>1 (10%)</td>
<td></td>
</tr>
<tr>
<td>Hearing loss, n (%)</td>
<td>UTI+ (n = 2)</td>
<td>UTI− (n = 1)</td>
<td>0.3</td>
</tr>
<tr>
<td></td>
<td>2 (25%)</td>
<td>3 (27%)</td>
<td></td>
</tr>
<tr>
<td>Mobility dependence, n (%)</td>
<td>UTI+ (n = 3)</td>
<td>UTI− (n = 1)</td>
<td>.03</td>
</tr>
<tr>
<td></td>
<td>3 (38%)</td>
<td>5 (23%)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: SIRS, systemic inflammatory response syndrome; SD, standard deviation; UTI, urinary tract infection.

Table 2. Comparison of Top Canonical Pathways Between Groups After Adjusting for Systemic Inflammatory Response Syndrome.

<table>
<thead>
<tr>
<th>Group Comparison</th>
<th>Canonical Pathway</th>
<th>P Value</th>
<th>z Score(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>D+ versus D−</td>
<td>Complement system</td>
<td>.007</td>
<td>2.0</td>
</tr>
<tr>
<td>D+ UTI+ versus D− UTI+</td>
<td>None</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>D+ UTI+ versus D− UTI−</td>
<td>EIF4 and p70S6K</td>
<td>.01</td>
<td>2</td>
</tr>
<tr>
<td>UTI+ versus UTI−</td>
<td>Interferon</td>
<td>.002</td>
<td>2.5</td>
</tr>
<tr>
<td></td>
<td>Actin cytoskeleton</td>
<td>.00002</td>
<td>-3.3</td>
</tr>
<tr>
<td></td>
<td>Integrin</td>
<td>8.7 × 10(^{-8})</td>
<td>-2.9</td>
</tr>
<tr>
<td></td>
<td>Paxillin</td>
<td>.0003</td>
<td>-2.3</td>
</tr>
<tr>
<td></td>
<td>RhoA</td>
<td>.0004</td>
<td>-2.3</td>
</tr>
<tr>
<td>D+ UTI+ versus D− UTI−</td>
<td>Interferon</td>
<td>.00004</td>
<td>2.5</td>
</tr>
<tr>
<td>D+ UTI−</td>
<td>ACTIN CYTOSKELETON</td>
<td>.004</td>
<td>-2.5</td>
</tr>
<tr>
<td></td>
<td>Integrin</td>
<td>.002</td>
<td>-2.5</td>
</tr>
<tr>
<td></td>
<td>Paxillin</td>
<td>.003</td>
<td>-2.5</td>
</tr>
<tr>
<td></td>
<td>GLIOMA INVASIVENESS</td>
<td>.004</td>
<td>-2.2</td>
</tr>
<tr>
<td>D− UTI+ versus D− UTI−</td>
<td>None</td>
<td>n/a</td>
<td>n/a</td>
</tr>
</tbody>
</table>

Abbreviations: D+, delirious; D−, not delirious; n/a, not applicable; UTI+, urinary tract infection present; UTI−, urinary tract infection absent.

\(^a\)z score: A positive z score indicates upregulation of the pathway. A negative z score indicates downregulation of the pathway.

Prior to adjusting for SIRS criteria in the model for differential expression analysis between all delirious and nondelirious patients, hierarchical clustering separated patients into their respective groups as seen in Figure 2.

### Pathways Associated With Differences Between Delirious and Nondelirious Patients

The 670 genes differentially expressed with \( P < 0.05 \) were input into IPA, and canonical pathway analysis indicated activation of complement system pathways \( (P = 0.007, z \text{ score} = 2) \) across all samples, regardless of UTI status. When considering only the patients with UTI, no pathways were considered significantly activated or repressed. Meanwhile, when considering only the patients without UTI, regulation of eIF4 and p70S6 K signaling was upregulated in delirium \( (P = 0.01, z \text{ score} = 2) \).

### Effect of SIRS on the Activation of Interleukin-6 and Interleukin-8 Pathways

Prior to adjusting for SIRS criteria in the model for differential expression analysis between all delirious and nondelirious patients, enrichment analysis identified significant overrepresentation of genes in pathways related to response to interferon α/β signaling, platelet activation, and response to virus (Table 2).

**Interferon Signaling Is the Primary Pathway Distinguishing Delirium With UTI Versus Delirium Due To An Unknown Etiology**

Compared to patients with delirium without an UTI, patients with delirium with an UTI had significant activation of the interferon signaling pathway \( (P = 0.00004, z \text{ score} = 2.5) \) as well as notable upstream activation of cytokines and transcriptional regulators (25.8% and 22.6% of all activated upstream regulators with unadjusted \( P < 0.05 \) and \( z \text{ score} > 2 \), respectively). Patients with delirium with an UTI had significant repression of the following signaling: integrin \( (P = 0.002, z \text{ score} = -2.5) \), paxillin \( (P = 0.003, z \text{ score} = -2.5) \), actin cytoskeleton \( (P = 0.004, z \text{ score} = -2.5) \), and glioma invasiveness \( (P = 0.004, z \text{ score} = -2.4) \). When analyzing all patients with an UTI, compared to all patients without an UTI, interferon signaling was also significant \( (P = 0.002, z \text{ score} = 2.5) \).

**Transcriptomic Profiling Separates Delirious From Nondelirious Patients**

Differential expression analysis of patients with delirium of any etiology versus no delirium resulted in 670 differentially expressed genes at unadjusted \( P < 0.05 \), for which ToppGene enrichment analysis found overrepresentation of functional elements related to mitochondrial structure and metabolism of heme. The subset of 123 genes with unadjusted \( P < 0.01 \) as features, hierarchical clustering separated patients into their respective groups as seen in Figure 2.
patients, both the interleukin (IL)-6 pathway and the IL-8 pathway were identified as activated by z score (2.1 and 2.9, respectively). However, the overlap \( P \) values were not statistically significant (0.294 and 0.236, respectively). After correction for SIRS, IL-6 was no longer identified as activated, but IL-8 was activated with a z score of 3.

**Discussion**

We used whole transcriptome profiling to look broadly at gene expression changes of participants with delirium due to UTI compared to those without UTI and between patients with and without delirium. The differential expression between any of these groups was subtle, with no genes being differentially expressed with an imposed adjusted \( P \) value of < 0.05. Thus, we relaxed this condition and used ranked unadjusted \( P \) values combined with filtering by pathway specific z scores to detect obscured or weak signals. Using this more sensitive approach, we showed that patients with delirium with an UTI, when compared to patients with delirium without an UTI, displayed significant activation of the interferon signaling pathway, upstream cytokines, and transcriptional regulators, as would be expected for infections, as well as repression of integrin, actin cytoskeleton, paxillin, and glioma invasiveness signaling. For all patients with delirium, compared to patients without delirium, there was significant activation of the complement system. When examining only patients without UTI, there was significant activation of the pathways for elf4 and p70S6K regulation in patients with delirium. These results highlight several pathways that may be implicated in distinguishing patients with delirium from those without delirium, and further, in distinguishing delirium due to specific etiologies.

Interferons are cytokines with immunomodulatory properties and have been associated with delirium. Our data demonstrate that interferon signaling is significantly upregulated for patients with delirium with an UTI, when compared to patients with delirium without an UTI. However, interferon signaling was not significantly upregulated, among nondelirious patients with an UTI compared to those without. This suggests that there may be a synergistic biological response when delirium is paired with infection, compared with the 2 processes in isolation. This distinction is also made in one recent prospective case–control study that included 47 patients with concomitant delirium and sepsis, 36 patients with delirium without sepsis, 36 patients with sepsis only, and 36 patients with neither delirium nor sepsis (control). Interferon \( \gamma \) was elevated in all groups except for the controls but was most elevated for patients with concurrent delirium and sepsis.

The complement pathway has been infrequently studied in patients with delirium. Activation of the complement system is typical of an organism’s stress response, and one recent study has detected activated complement in a prospective cohort study using proteomic analysis of cerebrospinal fluid
in patients with delirium. In our investigation, there was significant activation of the complement system in patients with delirium compared to those without delirium, but this was not found in the other group comparisons. Thus, this finding is of unknown clinical significance; however, given that complement activation is a potential therapeutic target in a wide range of pathologies, further study using proteomic methods to probe for the activated forms of complement is warranted.

Activation of the cytokine IL-6 and IL-8 pathways has been associated with delirium in prior studies, but we were unable to replicate this finding, especially when correcting for SIRS status. Increased serum levels of IL-6 and IL-8 have been found in association with postoperative delirium in several prospective cohorts of older patients admitted for hip fracture surgery. In 1 patient, the highest levels of IL-6 were ascertained during active delirium—particularly if the delirium was classified as hyperactive or mixed, rather than hypoactive,—whereas IL-8 was highest prior to development of delirium. In a separate case–control study that enrolled older patients admitted for either elective or emergent surgery, a multivariate analysis of preoperative serum samples revealed that increased levels of IL-6 were associated with a greater risk of postoperative delirium. However, our data suggest that IL-6 and IL-8 may be more tightly correlated with a heightened inflammatory response than to delirium itself.

While RNA-Seq is new to the field of delirium research, this technique has already benefited several other areas of medicine. Patterns of peripheral blood gene expression differ in patients with pulmonary infections, distinguishing participants with a respiratory viral infection from uninfected participants, as well as delineating between viral and bacterial infection with high (93%) specificity. A targeted reverse transcription polymerase chain reaction assay measuring the expression of these genes was validated in a prospective emergency department cohort with 89% sensitivity and 94% specificity. Such an assay has the potential to increase diagnostic accuracy and bolster directed treatment. This technique is most advanced in breast oncology, where a 21-gene signature (OncoDx) classifies tumors by prognosis based on gene profiling, allowing targeted use of adjuvant chemotherapies. Our exploratory research suggests that RNA-Seq may have the ability to distinguish between different causes of delirium, and thus, further investigation using larger cohorts with equally rigorous entry criteria and phenotyping is warranted.

This investigation features several strengths. All participants were evaluated and classified by a board-certified neurologist. We corrected for SIRS in our analysis to control for a heightened inflammatory state, as many of the pathways under investigation corresponded with inflammation. Whereas prior studies were limited by the need to specify which few serum or cerebrospinal fluid markers to study, the RNA-Seq approach we employed enabled us to uncover pathways not previously associated with delirium, albeit in an exploratory manner.

**Limitations**

This study is preliminary and has a few limitations. The sample size for this investigation is small. Null results may be due to both small numbers of patients and heterogeneity. An additional limitation is the issue of subject matching. Although sex was similar between delirious and nondelirious patients, patients with delirium were older and had higher rates of dementia in addition to other risk factors for delirium. Lack of a robust matching mechanism and a small sample size that precluded the possibility of multivariable modeling raise the potential for confounding by these factors. Overall, differential expression among the groups was subtle, with fewer than 10 genes differentially expressed at an adjusted \( P \) value of <.05 \((P_{adj})\), and thus, we explored weaker signals by utilizing unadjusted \( P \) values and \( z \) score statistics for pathway enrichment. While we detected expected pathways using this approach, such as interferon signaling in UTI(+) versus UTI(−) patients, our approach is susceptible to false positives and is also dependent on the particular gene pathways that are defined in the current IPA database.

Since the aim of our study focused on measuring serum biomarkers at a single point in time, we did not perform longitudinal delirium assessments. Because of caregiver and provider interviews during patient identification and enrollment, it is unlikely that patients identified as nondelirious were delirious prior to study. However, it is possible that nondelirious patients developed delirium at a later time during the hospitalization following enrollment. Retrospective review of patient charts identified only 1 nondelirious patient who developed a confusional state 5 days following his blood draw; while it is unlikely that this affected our analysis, one would expect misclassification of this type to bias toward the null. Longitudinal assessment will be important for future studies, especially in measuring how gene signaling may change in association with delirium persistence and resolution.

**Conclusions**

There are differences in gene expression between patients with delirium due to UTI compared to those without UTI, as well as between patients with and without delirium. Whole transcriptome profiling may help differentiate between causes of delirium and shed light onto its pathophysiology. Follow-up studies using a larger cohort are needed to formally validate the use of a transcriptomic classifier of delirium etiology, but such an understanding may advance the treatment of delirium by preventing unnecessary testing.

**Authors’ Note**

Katrina Kalantar and Sara C. LaHue contributed equally to the manuscript. Michael R. Wilson and Vanja C. Douglas contributed equally to the genesis of this study. Vanja C. Douglas, Michael R. Wilson, and Joseph L. DeRisi contributed to study concept and design. All authors contributed to acquisition, analysis, or interpretation of data; drafting of the manuscript was handled by Sara C. LaHue and Katrina Kalantar; critical revision of the manuscript for important intellectual
content was performed by Vanja C. Douglas, Michael R. Wilson, Scott A. Josephson, Joseph L. DeRisi, and Caitlin A. Contag; statistical analysis by Katrina Kalantar, Sara C. LaHue, and Caitlin A. Contag; funding was obtained by Vanja C. Douglas and Michael R. Wilson; administrative, technical, or material support by Hannah A. Sample; study was supervised by Vanja C. Douglas and Michael R. Wilson.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Supported by UCSF-RAP (M.R.W., V.C.D., H.A.S.) and National Center for Advancing Translational Sciences of the NIH (KL2TR000143; M.R.W.).

Supplemental Material
Supplemental material for this article is available online.

References


